BMY241101C38000
- 0.00
- 0.000.00%
Bristol-Myers Squibb Newsroom
Jim Cramer Says Bristol-Myers Squibb Company (BMY) Is 'Too Low'
Biogen Names Former Bristol-Myers Executive as Medical Chief
Express News | The third day of the medical insurance negotiation "opened", with enterprises such as Zaidong, Dize, and Shenwei entering the scene.
Correction to Bristol-Myers Squibb 2024 Guidance Headline on July 26
OS Therapies Appoints Two Bio-Pharmaceutical Industry Veterans to the Board of Directors
Bristol Myers Shares New Data on COBENFY for Schizophrenia at Psych Congress, Highlighting Long-Term Safety and Patient Satisfaction
Bristol Myers Squibb to Present New Clinical and Health Economics and Outcomes Research Data at Psych Congress 2024
Apple, Microsoft, Exxon, and More Stocks to Watch
Heard on the Street: Pfizer's Activist Battle Might Fizzle -- but Its Stock Probably Won't -- WSJ
Earnings Preview: BMY to Report Financial Results Pre-market on October 31
$Bristol-Myers Squibb(BMY.US)$ is scheduled to release its financial results pre-market on October 31 ET. Earnings PreviewAnalysts estimate $Bristol-Myers Squibb(BMY.US)$ to post revenue of USD11.25
Bristol-Myers Squibb Analyst Ratings
Express News | Bristol-Myers Squibb : Deutsche Bank Raises Target Price to $48 From $45
Citi Downgrades Bristol-Myers Squibb(BMY.US) to Hold Rating, Cuts Target Price to $55
Express News | Bristol-Myers Squibb Co : Citigroup Cuts to Neutral From Buy
Chen Jining meets with the Chief Executive Officer of Bristol-Myers Squibb in the USA, Giovanni Caforio.
This morning, the Secretary of the Shanghai Municipal Party Committee, Chen Jinong, met with the CEO Bosch of the American Bristol-Myers Squibb. Chen Jinong said, welcoming Bristol-Myers Squibb to bring more new projects, new technologies, and new models to Shanghai on the basis of existing good cooperation, further deepen clinical research, promote new drug development, layout production manufacturing, participate in health insurance development, better benefit the general patients, and help the high-quality development of the biomedical industry in Shanghai.
We Think Bristol-Myers Squibb (NYSE:BMY) Can Stay On Top Of Its Debt
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
800% Upside For This Biotech Stock - Analyst Initiates Coverage On Bladder Cancer Focused ImmunityBio
Why Is Evotec Stock Gaining Today?
Sector Update: Health Care Stocks Steady Premarket Wednesday